Delivery Order SPE2DB22D1041-SPE2DB25FUBL2
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,814.83 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. The contract is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The award was executed on June 2, 2025, with an ultimate completion date of June 3, 2025, and performance...
- The Defense Logistics Agency awarded a delivery order valued at $1,202.16 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (150 mL), a medication used to treat attention deficit hyperactivity disorder. The award was made on July 21, 2025, with a completion date of July 22, 2025, under a firm fixed-price delivery order contract with no set-aside designation. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $1,925.08 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), a pharmaceutical product used in treating attention deficit hyperactivity disorder. This firm fixed-price delivery order, issued on August 18, 2025, with an ultimate completion date of August 19, 2025, represents a non-competitive award under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The place of...
- The Defense Logistics Agency awarded a delivery order valued at $1,764.78 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml), a medication commonly used to treat attention deficit hyperactivity disorder. This firm fixed-price delivery order, awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a non-competitive set-aside award. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency (DLA) awarded a $1,896.96 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. This firm fixed-price delivery order was competitively awarded with no set-aside designation and carries an ultimate completion date of July 23, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $1,464.90 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL), a medication commonly used to treat attention deficit hyperactivity disorder. This firm fixed-price delivery order, awarded on August 6, 2025, is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through...
- The Defense Logistics Agency awarded a delivery order valued at $3,308.96 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. This competitively awarded, firm fixed price delivery order was issued on September 2, 2025, with an ultimate completion date of September 3, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,467.42 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. This firm fixed-price delivery order, issued on September 8, 2025, with completion expected by September 9, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $3,056.16 firm fixed price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (120 mL), a medication used to treat attention deficit hyperactivity disorder. This non-set-aside competitive award was made on September 9, 2025, with an ultimate completion date of September 10, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a single transaction fulfilling...
- The Defense Logistics Agency awarded a delivery order valued at $1,577.04 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) on July 29, 2025, with completion scheduled for July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- SPE2DB22D1041Indefinite Delivery Contract
- SPE2DB22D1041-SPE2DB25FUBL2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,609.51 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml Suspension (180 ml), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price delivery order was issued on August 14, 2025, with an ultimate completion date of August 15, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating it was competed among qualified vendors in the open market. This delivery order is issued under AmerisourceBergen Drug Corp's prime Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a leading pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of medications and medical supplies to support military healthcare systems and the Defense Health Agency. The parent IDC serves as a global pharmaceutical support vehicle enabling the company to fulfill diverse medical supply requirements across multiple therapeutic domains for federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 8/14/25 |